Scholarlink

<p>GLP-1 receptor agonists revolutionized diabetes therapy and offer cardiorenal protection in diabetic kidney disease. Their potential in Autosomal Dominant Polycystic Kidney Disease (ADPKD) is now being explored. Preclinical findings and metabolic improvements (obesity, hypertension, inflammation) indicate promise. Further clinical studies are required to ensure efficacy and safety before clinical integration can be considered.</p><p> <?noindent??><b>Clinical trial number</b>: Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Hamad Ali,
  • Barrak Alahmad,
  • Fahd Al-Mulla

摘要

GLP-1 receptor agonists revolutionized diabetes therapy and offer cardiorenal protection in diabetic kidney disease. Their potential in Autosomal Dominant Polycystic Kidney Disease (ADPKD) is now being explored. Preclinical findings and metabolic improvements (obesity, hypertension, inflammation) indicate promise. Further clinical studies are required to ensure efficacy and safety before clinical integration can be considered.

Clinical trial number: Not applicable.